title: Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).
abstract: Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).
authors: PharmAbcine, Daejeon 305-811, Korea. biobuckeye@gmail.com
authors: Sang Hoon
authors: SH
authors: Lee
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D000882:Haplorhini; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D040301:Vascular Endothelial Growth Factor Receptor-2; C570591:olinvacimab